Navigation Links
NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
Date:9/6/2012

LAWRENCE, Mass., Sept. 6, 2012 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it submitted public comments to the Centers for Medicare and Medicaid Services (CMS) regarding its Proposed Rule for the Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System for 2013. NxStage's comments call for CMS to correct the current insufficient and inequitable payments for home hemodialysis (HHD) training—making this life-changing modality more accessible to Medicare patients suffering from ESRD.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

The Company calls for these changes based upon:

  • Recognition by experts of the limitations of conventional modalities in addressing specific health conditions;
  • Clinical data supporting superior patient outcomes with more frequent HHD vs. conventional dialysis;
  • Multiple third-party surveys showing that nephrologists and other healthcare professionals would choose HHD most often for themselves if faced with ESRD; and
  • A Congressional mandate for CMS to develop policy that encourages more patients to be treated in the home setting.

"The current Medicare payment system doesn't provide adequate reimbursement for patients to be trained on HHD and represents an unintended injustice to those patients who wish to perform HHD," said Joe Turk, President, North America, NxStage Medical, Inc. "The status quo is inconsistent with the Congressional mandate to bring patients home and is a huge factor in Medicare ESRD patients' limited access to more frequent HHD. This issue can and should be addressed to allow patients better access to this life-changing therapy, that so often leads to longer, healthier lives for patients who require dialysis to live."

A copy of the Company's submission can be found at http://www.regulations.gov/#!documentDetail;D=CMS-2012-0080-0053.

About the NxStage System One

The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy.   When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand.  Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation. http://www.nxstage.com/.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2012. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:
Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients
2. NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference
3. NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
4. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
5. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
6. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
7. Bayer Submits New Drug Application for Regorafenib for the Treatment of Gastrointestinal Stromal Tumors (GIST)
8. Delcath Submits New Drug Application For Proprietary Chemosaturation System To The U.S. Food And Drug Administration
9. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
11. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Guerbet announced today that it has been named a ... One of 12 suppliers to receive the ... of Premier members through exceptional local customer service and ... lower costs. "We ... customer service from Premier," says Massimo Carrara , ...
(Date:6/23/2016)... Research and Markets has announced ... Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, ... offering. Surgical Procedure ... planners, provides surgical procedure volume data in a geographic ... in-depth analysis of growth drivers and inhibitors, including world ...
(Date:6/23/2016)... , June 23, 2016 The ... it continues to present great opportunities to investors. Stock-Callers.com ... today: Intrexon Corp. (NYSE: XON ), Vertex ... Inc. (NASDAQ: ARNA ), and Regeneron Pharmaceuticals ... these stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):